Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intracerebral hemorrhage is the least treatable form of stroke. We performed this phase 3 trial to confirm a previous study in which recombinant activated factor VII (rFVIIa) reduced growth of the hematoma and improved survival and functional outcomes. METHODS: We randomly assigned 841 patients with intracerebral hemorrhage to receive placebo (268 patients), 20 microg of rFVIIa per kilogram of body weight (276 patients), or 80 microg of rFVIIa per kilogram (297 patients) within 4 hours after the onset of stroke. The primary end point was poor outcome, defined as severe disability or death according to the modified Rankin scale 90 days after the stroke. RESULTS: Treatment with 80 microg of rFVIIa per kilogram resulted in a significant reduction in growth in volume of the hemorrhage. The mean estimated increase in volume of the intracerebral hemorrhage at 24 hours was 26% in the placebo group, as compared with 18% in the group receiving 20 microg of rFVIIa per kilogram (P=0.09) and 11% in the group receiving 80 microg (P<0.001). The growth in volume of intracerebral hemorrhage was reduced by 2.6 ml (95% confidence interval [CI], -0.3 to 5.5; P=0.08) in the group receiving 20 microg of rFVIIa per kilogram and by 3.8 ml (95% CI, 0.9 to 6.7; P=0.009) in the group receiving 80 microg, as compared with the placebo group. Despite this reduction in bleeding, there was no significant difference among the three groups in the proportion of patients with poor clinical outcome (24% in the placebo group, 26% in the group receiving 20 microg of rFVIIa per kilogram, and 29% in the group receiving 80 microg). The overall frequency of thromboembolic serious adverse events was similar in the three groups; however, arterial events were more frequent in the group receiving 80 microg of rFVIIa than in the placebo group (9% vs. 4%, P=0.04). CONCLUSIONS: Hemostatic therapy with rFVIIa reduced growth of the hematoma but did not improve survival or functional outcome after intracerebral hemorrhage. (ClinicalTrials.gov number, NCT00127283 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1965) · PubMed · Cited by 14,925
ASSESSMENT OF COMA AND IMPAIRED CONSCIOUSNESS
Teasdale, G., & Jennett, B. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91639-0 · Cited by 13,215
Functional evaluation : Barthel index
Mahonery, F. I. (1965) · Medical Entomology and Zoology · Cited by 12,762
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Measurements of acute cerebral infarction: a clinical examination scale.
Brott, T., Adams, H. P., Olinger, C. P., Marler, J. R., Barsan, W. G., Biller, J., Spilker, J., Holleran, R., Eberle, R., & Hertzberg, V (1989) · Stroke · doi:10.1161/01.str.20.7.864 · Cited by 5,911
WILSON, J. T. L., PETTIGREW, L. E. L., & TEASDALE, G. M. (1998) · Journal of Neurotrauma · doi:10.1089/neu.1998.15.573 · Cited by 2,386
The ICH Score: A Simple, Reliable Grading Scale for Intracerebral Hemorrhage
Hemphill, J. C., Bonovich, D. C., Besmertis, L., Manley, G. T., & Johnston, S. C. (2001) · Stroke · doi:10.1161/01.str.32.4.891 · Cited by 2,196
Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality.
Broderick, J. P., Brott, T. G., Duldner, J. E., Tomsick, T., & Huster, G. (1993) · Stroke · doi:10.1161/01.str.24.7.987 · Cited by 1,746
Self-citationEarly Hemorrhage Growth in Patients With Intracerebral Hemorrhage
Brott, T., Broderick, J., Kothari, R., Barsan, W., Tomsick, T., Sauerbeck, L., Spilker, J., Duldner, J., & Khoury, J. (1997) · Stroke · doi:10.1161/01.str.28.1.1 · Cited by 1,477
Self-citationHematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage
Davis, S. M., Broderick, J., Hennerici, M., Brun, N. C., Diringer, M. N., Mayer, S. A., Begtrup, K., & Steiner, T. (2006) · Neurology · doi:10.1212/01.wnl.0000208408.98482.99 · Cited by 1,168
Self-citation
Research works printed but not linked: 2
- Zimmerman RD, 2006, AJNR Am J Neuroradiol, 27, 666
- Mahoney FI, 1965, Md State Med J, 14, 61
Cited by
Items 901–1,000 of 1,000
Brissette, V., Ouyang, M., Yogendrakumar, V., Ramsay, T., Mallick, R., Morotti, A., Goldstein, J. N., Qureshi, A. I., Anderson, C. S., & Dowlatshahi, D. D. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.049096 · Cited by 2
Rincón, F., & Mayer, S. A. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511977558.024 · Cited by 2
Self-citationIntracerebral and Subarachnoid Hemorrhage
Marik, P. E. (2014) · Springer eBooks · doi:10.1007/978-3-319-11020-2_43 · Cited by 2
Therapeutic strategies and neurorehabilitation
Brainin, M., & Heiss, W. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107239340.018 · Cited by 2
Management von schwerwiegenden intrazerebralen Blutungen unter Antikoagulation
Kuramatsu, J. B., Gerner, S. T., Huttner, H. B., & Schwab, S. (2017) · Aktuelle Neurologie · doi:10.1055/s-0043-108908 · Cited by 2
“Nach den negativen Ergebnissen und den Sicherheitsbedenken mit einer erhöhten Rate an thrombembolischen Komplikationen des FAST-Trials, einer Phase-3-Studie zur Wirksamkeit von rekombinanten aktivierten Faktor VII (rFVIIa) bei ICB-Patienten, kann die Verabreichung von rFVIIa aktuell nicht empfohlen werden [1, 61].”
BackgroundCaplan, L. R. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4721-6.50007-9 · Cited by 2
Medication-Use Evaluation of Recombinant Human Factor VIIa
Al-Subhi, A., Khan, M. A., & Aseeri, M. A. (2020) · Global Journal on Quality and Safety in Healthcare · doi:10.36401/jqsh-19-41 · Cited by 2
Use of Low-Dose Recombinant Factor Ⅶa for Uncontrolled Perioperative Bleeding
Chang, Z., Chu, X., Chen, W. L., Hu, J.-H., Gong, J., Liu, D., He, Q. W., Feng, Z., Xiao, S.-R., & Liu, Y. (2020) · Dose-Response · doi:10.1177/1559325820969569 · Cited by 2
Ansari, A. M., Khorasanchi, A., Faghihimehr, A., & Toor, A. A. (2021) · Clinical Case Reports · doi:10.1002/ccr3.4788 · Cited by 2
Tang, M., Shin, H. J., Metcalf-Doetsch, W., Luo, Y., Lindholm, P. F., Kwaan, H. C., & Naidech, A. M. (2021) · Neurocritical Care · doi:10.1007/s12028-021-01369-z · Cited by 2
L’utilisation du placebo dans les essais cliniques est-elle légitime ?
Durand, G. (2024) · Éthique & Santé · doi:10.1016/j.etiqe.2024.05.002 · Cited by 2
Wartenberg, K. E., & Mayer, S. A. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139344296.014 · Cited by 2
Self-citationSuccessful use of recombinant factor VIIa in a preterm infant with life-threatening haematuria
Faust, K., Tröger, B., Kahl, F., Schumacher, M., Göpel, W., & Härtel, C. (2009) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32832f6c40 · Cited by 2
Nontraumatic Intracerebral and Subarachnoid Hemorrhage
Zazulia, A. R., & Diringer, M. N. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1367-1.00035-5 · Cited by 2
Self-citationPhantom-based standardization of CT angiography images for spot sign detection
On Behalf of ATACH-II and NETT Investigators, Morotti, A., Romero, J. M., Jessel, M. J., Hernandez, A. M., Vashkevich, A., Schwab, K. M., Burns, J. D., Shah, Q. A., Bergman, T. A., et al. (2017) · Neuroradiology · doi:10.1007/s00234-017-1857-4 · Cited by 2
“On the other hand, when selecting for therapies with potential harm such as prohemostatic drugs, it may be that higher specificity is needed, in which case a simple HU cutoff may be best [24].”
BackgroundHemostatic therapy for intracerebral hemorrhage
Ziai, W., & Mayer, S. A. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511691836.022 · Cited by 2
Self-citationIntensivmedizinische Versorgung von Patienten mit intrazerebraler Blutung
Diedler, J., Sykora, M., Herweh, C., Orakcioglu, B., Zweckberger, K., Steiner, T., & Hacke, W. (2011) · Der Nervenarzt · doi:10.1007/s00115-010-3072-y · Cited by 2
Self-citationRun-up to participation in ATACH II in Japan.
Toyoda, Ḱ., Sato, S., Koga, M., Yamamoto, H., Nakagawara, J., Furui, E., Shiokawa, Y., Hasegawa, Y., Okuda, S., Sakai, N., et al. (2012) · Europe PMC (PubMed Central) · Cited by 2
Freeman, W. D., & Aguilar, M. I. (2010) · Aging Health · doi:10.2217/ahe.10.45 · Cited by 2
“The evaluation and management of warfarin intracranial bleeding is outside of the scope of this article but references are provided [5,26,44–49].”
BackgroundMaking Sense of Recent Acute Stroke Trial Results
Yassi, N., Michel, P., & Parsons, M. W. (2014) · Current Radiology Reports · doi:10.1007/s40134-014-0046-z · Cited by 2
“Whereas the phase-3 trial of recombinant activated factor VII (rFVII) did not demonstrate benefit [63], the ongoing Spot Sign for”
BackgroundIntracerebral Hemorrhage: A Transition Phase Toward Better Prognosis
Maira, G., & Doglietto, F. (2011) · World Neurosurgery · doi:10.1016/j.wneu.2011.12.076 · Cited by 2
Responses to acute stroke: beyond urgent imaging and systemic thrombolysis, where to now?
Dawson, J., & Quinn, T. J. (2012) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2012.201 · Cited by 2
Hemorrhage Control and Thrombosis Following Severe Injury
Zimrin, A. B., Bai, Y., Holcomb, J. B., & Hess, J. R. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2296-9.00045-2 · Cited by 2
Sekhon, M. S., & Griesdale, D. E. G. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781316146187 · Cited by 2
Secondary Prevention of Cardioembolic Stroke
Furie, K. L., & Khan, M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-29544-4.00062-1 · Cited by 2
Overview of Hemorrhagic Stroke Care in the Emergency Unit
Kreitzer, N. P., & Woo, D. (2018) · Stroke revisited · doi:10.1007/978-981-10-1427-7_7 · Cited by 2
Hemostatic Agents in Critically Ill Patients
Das, S. K., & Reddy, M. M. (2019) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-23258 · Cited by 2
Sakuta, K., Yaguchi, H., Sato, T., Mukai, T., Komatsu, T., Sakai, K., Mitsumura, H., Okuno, K., Tanaka, T., & Iguchi, Y. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116834 · Cited by 2
Qian, H., Chen, S., Chen, Y., Chang, Y., Li, Y., Dou, S., Chen, Q., Wang, G., & Xie, M. (2021) · The Neurologist · doi:10.1097/nrl.0000000000000375 · Cited by 2
Intracerebral Hemorrhage (ICH) Approach: Bedside Practical Review
Cusack, T. J., & Ziai, W. (2021) · Springer eBooks · doi:10.1007/978-3-030-81419-9_3 · Cited by 2
Anderson, C. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-69424-7.00028-4 · Cited by 2
Intracranial Hemorrhage Focused on Cancer and Hemato-Oncologic Patients
Khorchid, Y. M., & Malkoff, M. D. (2018) · Springer eBooks · doi:10.1007/978-3-319-74698-2_40-1 · Cited by 2
Head trauma: anesthetic considerations and management
Dagal, A., & Lam, A. M. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781139814713.026 · Cited by 2
Urgent warfarin reversal: know your options
Pendergrast, J. M. (2010) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-010-9284-6 · Cited by 2
Guerrero-López, F., & Miñambres, E. (2009) · Medicina Intensiva · doi:10.1016/s0210-5691(09)71214-8 · Cited by 2
Brunkhorst, R., & Foerch, C. (2012) · Stroke · doi:10.1161/strokeaha.112.651976 · Cited by 2
CORRECTION OF COAGULOPATHY SECONDARY TO ORAL AND PARENTERAL ANTICOAGULANTS
Aiyagari, V. (2009) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000348823.04125.eb · Cited by 2
“Unauthorized reproduction of this article is prohibited. was normalized by 30 minutes after PCC infusion in 93% of patients, and clinical hemostatic efficacy was classified as good or satisfactory in 98% of patients (Pabinger et al, 2008).”
BackgroundHematoma Enlargement as a Target for Treating Intracerebral Hemorrhage
Grotta, J. C. (2021) · Neurology · doi:10.1212/wnl.0000000000012391 · Cited by 2
Vascular Diseases of the Nervous System
Kase, C. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0434-1.00063-3 · Cited by 2
Nakagawa, N. (2016) · Japanese Society of Pediatric Cardiology and Cardiac Surgery · doi:10.9794/jspccs.32.9 · Cited by 1
Surgery for Spontaneous Intracerebral Hemorrhage: Current Concept
Ray, P. S. (2021) · Indian Journal of Neurosurgery · doi:10.1055/s-0041-1726865 · Cited by 2
Analysis of Influencing Factors of Early Hematoma Enlargement in Primary Cerebral Hemorrhage
王, 子. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1391935 · Cited by 1
The latest therapeutic advances with spontaneous intracerebral hemorrhage
Griffin, M., Kwok, C. S., Qureshi, A. I., & Lip, G. Y. H. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2502048 · Cited by 1
“In ANNEXA-I, as with multiple other trials, differences in hematoma expansion were not followed by improvements in functional outcomes or mortality [23,24].”
Sousa, J. A., Pancorbo, O., Simonetti, R., Llull, L., Coscojuela, P., Blasco, J., Pérez‐Hoyos, S., García‐Tornel, Á., Rodríguez‐Villatoro, N., Rizzo, F., et al. (2026) · European Stroke Journal · doi:10.1093/esj/aakaf024 · Cited by 1
Hsieh, P.-F., Liu, Y.-B., Cordonnier, C., & Tsai, H.-H. C. (2026) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2026.103423 · Cited by 1
“Recombinant activated factor VIIa (rFVIIa) reduced hematoma growth in the Factor Seven for Acute Hemorrhagic Stroke trial but did not improve functional outcomes and increased thromboembolic risk [6].”
Chen, L., Hong, C., Guo, X., Liu, J., Cai, J., Chen, L., 毛更生, Xue, M., Pu, J., Kang, D., et al. (2026) · Journal of Neurorestoratology · doi:10.1016/j.jnrt.2026.100295 · Cited by 1
Wang, J., Wu, C., Guo, J., Yang, Z., He, L., Chen, S., & Zhang, L. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1829603 · Cited by 1
Nischal, S. A., Patel, S., Kale, K. M., & Murphy, M. M. (2026) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2026-339391 · Cited by 1
Cognitive Dysfunction After Intracerebral Hemorrhage, Vasculitis, and Other Stroke Syndromes
Smith, E. E., & Venegas-Torres, J. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7672-6_11 · Cited by 2
Neurosurgery in Hemorrhagic Stroke
Etminan, N., Beseoglu, K., & Hänggi, D. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_108 · Cited by 2
Manolis, A. S., Manolis, T. A., & Melita, H. (2013) · Hospital chronicles/Hospital Chronicles · doi:10.2015/hc.v8i4.564 · Cited by 3
Blood pressure reduction for acute intracerebral hemorrhage: How low can you go?
Szeder, V., & Mayer, S. A. (2008) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-008-0080-4 · Cited by 1
“Over the past decade, large clinical trials of surgical hematoma evacuation and ultra-early hemostatic therapy did demonstrate consistently improved outcomes [3, 4 ].”
BackgroundInfluentialSelf-citationSevrez, C., Thouvenin, S., Choppard, B., Fouyssac, F., Baleydier, F., Chambost, H., Deméocq, F., Plantaz, D., Girard, P., Guitton, C., et al. (2014) · Revue d Oncologie Hématologie Pédiatrique · doi:10.1016/j.oncohp.2014.07.003 · Cited by 1
New Drugs and Devices from 2011-2012 That Might Change Your Practice
Lex, J. (2013) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2013.2.16210 · Cited by 1
d’Esterre, C. D. (2013) · Scholarship@Western (Western University) · Cited by 1
Risk Factors for Enlargement of Intracerebral Hematoma after Hospitalization
Koseki, H., Arai, N., Kuroi, Y., Hana, T., Ohbuchi, H., Hirota, K., Hagiwara, S., Shigeru, T. A. N. I., Sasahara, A., & Kasuya, H. (2013) · Surgery for Cerebral Stroke · doi:10.2335/scs.41.187 · Cited by 1
Audebert, H. J. (2011) · Notfall + Rettungsmedizin · doi:10.1007/s10049-011-1472-6 · Cited by 1
The Challenges of Conducting Clinical Trials in Diseases with Small Target Populations
Arkin, S. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782624202-00053 · Cited by 1
Surgery for Intracerebral Hemorrhage
Mendelow, A. D., & GREGSON, B. A. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-5478-8.10069-7 · Cited by 1
Risk predictors to limit neuronal loss after intracerebral haemorrhage
Gurol, M. E. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30313-2 · Cited by 1
Schoemaker, R. C., Nayak, S., Harnisch, L. O., & Karlsson, M. O. (2019) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-019-09653-4 · Cited by 1
Neurochirurgische Intensivmedizin
Beynon, C., Bernhard, M., Brenner, T., Dietrich, M., Fiedler, M. O., Nußhag, C., Weigand, M. A., Reuß, C. J., Michalski, D., & Jungk, C. (2021) · Der Anaesthesist · doi:10.1007/s00101-021-00978-9 · Cited by 1
“Hierfür wurdendie individuellenTeilnehmerdaten von über 4172 Patienten aus 3 prospektiven Studien („Antihypertensive treatment of acute cerebral hemorrhage II“ [22]; „Ethnic/racial variations of intracerebral hemorrhage study“ [29]; „Recombinant factor VIIa in acute intracerebral hemorrhage trial“ [19]) eingeschlossen…”
BackgroundKutty, S. A. (2017) · InTech eBooks · doi:10.5772/66867 · Cited by 1
“Though initial trials with recombinant activated factor VII (rFVIIa) showed promise in limit‐ ing the hematoma size following early administration of the drug to patients with intracere‐ bral hemorrhage, this was not borne out in phase three trials [59, 60] Furthermore, the use of rFVIIa has been associated with an in…”
BackgroundDomeño, A. M., & Martí‐Fábregas, J. (2015) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(15)30003-2 · Cited by 2
Intrazerebrale Blutung – Ursachen, Diagnostik, Therapie
Staykov, D. (2017) · Fachwissen Pflege · doi:10.1007/978-3-662-53625-4_8 · Cited by 1
Cerebralamyloid angiopathy-related intracranial hemorrhage
Skolarus, L. E., & Jacobs, T. L. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511997426.089 · Cited by 1
Multimodal treatment of post‐tissue plasminogen activator‐related intracerebral haemorrhage
Varma, D. D., Chen, C., McDONALD, M., & Lee, A. (2012) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2011.02694.x · Cited by 1
Accident vasculaire cérébral hémorragique
Bruder, N. J., & Velly, L. J. (2013) · Springer eBooks · doi:10.1007/978-2-287-99031-1_5 · Cited by 2
Cook, D. J., & Tymianski, M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7672-6_2 · Cited by 1
Anoxic-Ischemic Encephalopathy and Strokes Causing Impaired Consciousness
Bussière, M., & Young, G. B. (2011) · Neurologic Clinics · doi:10.1016/j.ncl.2011.07.001 · Cited by 1
“Although early administration of recombinant factor VIIa may limit hematoma expansion, no clear benefit was demonstrated in recent trials in an unselected population.(56) Surgical decompression is not routinely recommended”
Rol del factor VII recombinante activado en pacientes neuroquirúrgicos y neurocríticos
Rama-Maceiras, P., Ingelmo, I., Julià, N. F., & Hernandez-Palazon, J. (2011) · Neurocirugía · doi:10.1016/s1130-1473(11)70016-1 · Cited by 1
Prise en charge des accidents vasculaires cérébraux à la phase aiguë
Degos, V., & Guidoux, C. (2012) · EMC-Anesthésie réanimation/Encyclopédie médico-chirurgicale. Anesthésie, réanimation · doi:10.1016/s0246-0289(12)57423-2 · Cited by 2
Kertland, H. R., & Tejani, A. M. (2012) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v65i5.1180 · Cited by 1
Antihypertensive therapy in acute cerebral haemorrhage
ROBERTIS, E. D., Romano, G. M., Marinosci, G. Z., Servillo, G., & Tufano, R. (2012) · Trends in Anaesthesia and Critical Care · doi:10.1016/j.tacc.2012.12.001 · Cited by 1
Meybodi, K. T., Taghvaei, M., Derakhshanrad, N., Khan, Z. H., & Saberi, H. (2014) · Archives of Neuroscience · doi:10.5812/archneurosci.18319 · Cited by 1
Varela, C. A., Reina, M. A. D., López, A., Galindo, S. V. G., Gómez, J. M. R., & Arruga, A. (2009) · Revista Española de Anestesiología y Reanimación · doi:10.1016/s0034-9356(09)70379-2 · Cited by 1
Haemostatic drugs for traumatic brain injury
Perel, P., Roberts, I., Shakur‐Still, H., Thinkhamrop, B., Phuenpathom, N., & Yutthakasemsunt, S. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007877.pub3 · Cited by 1
RetractedEvidências sobre diagnóstico e tratamento do acidente vascular encefálico no serviço de urgência
de Figueiredo, M. M., Bichuetti, D. B., & de Góis, A. F. T. (2012) · Diagn. tratamento · Cited by 12
Posttraumatic Cerebral Infarction: Incidence, Outcome, and Risk Factors
Dries, D. J. (2009) · Yearbook of Critical Care Medicine · doi:10.1016/s0734-3299(08)79153-6 · Cited by 1
Astroglial Proteins as Biomarkers of Intracerebral Hemorrhage
Foerch, C. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734745-00164 · Cited by 1
Coagulation problems in the critically ill
Lazo‐Langner, A. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107323919.008 · Cited by 1
Helfritz, F., & Stiefel, P. (2015) · Journal of Bioequivalence & Bioavailability · doi:10.4172/jbb.1000259 · Cited by 1
“, the total amount of rVIIa given to a patient does not seem to correlate with the development of thromboembolic events [25].”
BackgroundInfluentialArikán, F., Urzaiz, L. L., Alén, J. F., & Laez, R. M. (2017) · Neurocirugía (English Edition) · doi:10.1016/j.neucie.2017.08.001 · Cited by 1
Factor VII and thromboembolism
Cardoso, T., & Saraçoğlu, A. (2018) · Trends in Anaesthesia and Critical Care · doi:10.1016/j.tacc.2018.04.010 · Cited by 1
Prehospital and Emergency Department Management of Intracerebral Hemorrhage
Ishfaq, M. F., Goyal, N., Pandhi, A., & Malkoff, M. D. (2018) · Springer eBooks · doi:10.1007/978-3-319-77063-5_1 · Cited by 1
Thromboprophylaxis and Seizure Management in Intracerebral Hemorrhage
Kargiotis, O., Tsivgoulis, G. K., & Suárez, J. I. (2018) · Springer eBooks · doi:10.1007/978-3-319-77063-5_5 · Cited by 1
Hubungan ICH Score dengan Outcome Fungsional (Setelah 3 Bulan)
Putra, F., Frida, M., & Ahmad, B. (2018) · Jurnal Kesehatan Andalas · doi:10.25077/jka.v7i0.820 · Cited by 1
Transfusion and Coagulation Therapy
Tanaka, K. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1679-5.00036-3 · Cited by 2
Prevention and Treatment of Stroke
Fisher, M., & Önal, M. Z. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2930-6.00031-8 · Cited by 1
Intracranial Hemorrhage Focused on Cancer and Hemato-oncologic Patients
Khorchid, Y. M., & Malkoff, M. D. (2019) · Springer eBooks · doi:10.1007/978-3-319-74588-6_40 · Cited by 1
Dakakni, T., & James, M. L. (2012) · Wiley eBooks · doi:10.1002/9781118704950.ch4 · Cited by 1
Ma, Y., Zhang, P., Tang, Y., Yang, X., & Tang, Z. (2020) · Brain Hemorrhages · doi:10.1016/j.hest.2020.01.003 · Cited by 1
Ma, Y., Zhang, D., Lv, Z., Cui, Y., Fei, Y., Chang, T., Yu, M., Lü, J., Huang, Q., Zhang, Y., et al. (2021) · Medicine · doi:10.1097/md.0000000000024214 · Cited by 1
“In addition, based on the current research, it has been confirmed that neither surgical treatment nor current drug treatment is the most preferred treatment.([9,10]) In the face of the limitations of the treatment for cerebral hemorrhage, traditional Chinese medicine (TCM) is increasingly used to treat cerebral hemorr…”
BackgroundYoh, N. T., Sisti, J., Connolly, E. S., Chang, T. R., & Roh, D. J. (2021) · World Neurosurgery · doi:10.1016/j.wneu.2021.01.107 · Cited by 1
Prise en charge de l’Accident Vasculaire Cérébral (AVC) grave
Rosso, C. (2021) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2021.03.003 · Cited by 1
Aucutt‐Walter, N., Jewells, V. L., & Huang, D. Y. C. (2009) · Wiley eBooks · doi:10.1002/9781444306286.ch20 · Cited by 1
Clifford, L., & Kor, D. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-19668-8_35 · Cited by 2
Alternatives to Allogeneic Transfusion
Klein, H. G., & Anstee, F. D. J. (2013) · Wiley eBooks · doi:10.1002/9781118689943.ch18 · Cited by 1
Hematologic Interventions for Acute Central Nervous System Disease
Kumar, M. A., & Cucchiara, B. L. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2296-9.00042-7 · Cited by 1
Sekhon, M. S., & Henderson, W. R. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781316146187.010 · Cited by 1
Metadata
- Authors
- Mayer, S. A., Brun, N. C., Begtrup, K., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., & Steiner, T.
- Affiliations
- Columbia University Irving Medical Center (US)
- Novo Nordisk (Denmark) (DK)
- University of Cincinnati Medical Center (US)
- The Royal Melbourne Hospital (AU)
- Washington University in St. Louis (US)
- Heidelberg University (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-15
- Volume
- 358
- Issue
- 20
- Pages
- 2127-2137
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2142640478
- Cited by
- 1,255
- References
- 29
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 44 · 2023: 36 · 2022: 38 · 2021: 75 · 2020: 71 · 2019: 57 · 2018: 59 · 2017: 75 · 2016: 60 · 2015: 68 · 2014: 77 · 2013: 90 · 2012: 105
- FWCI
- 70.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Health Sciences › Medicine › Clinical Neurology › Intracranial Aneurysms: Treatment and Complications
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- recombinant factor VIIa, intracerebral hemorrhage, hematoma expansion, hemorrhagic stroke, thromboembolic adverse events, functional outcome, modified Rankin Scale, hemostatic therapy, dose comparison, arterial events, bleeding complications, arterial thrombosis, venous thromboembolism
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cerebral Hemorrhage, Double-Blind Method, Female, Hematoma, Humans, Male, Middle Aged, Recombinant Proteins, Tomography, X-Ray Computed, Glasgow Coma Scale, Factor VIIa, Treatment Failure, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.